ANIP
ANI Pharmaceuticals Inc.
$81.41
-$1.31(-1.58%)
70
Overall
75
Value
81
Tech
55
Quality
Market Cap
$1.94B
Volume
456.07K
52W Range
$57.33 - $99.50
Target Price
$109.88
Order:
Income Statement
| Metric | Trend | Chart | 2016 Dec | 2017 Dec | 2018 Dec | 2019 Dec | 2020 Dec | 2021 Dec | 2022 Dec | 2023 Dec | 2024 Dec | 2025 Dec |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| REVENUE | ||||||||||||
| Total Revenue | -- | -- | -- | -- | -- | -- | -- | $486.8M | $614.4M | $883.4M | ||
| Total Revenue | -- | -- | -- | -- | -- | -- | -- | $486.8M | $614.4M | $883.4M | ||
| COST OF GOODS SOLD | ||||||||||||
| Cost of Revenue | -- | -- | -- | -- | -- | -- | -- | $241.3M | $317.9M | $432.7M | ||
| GROSS PROFIT | ||||||||||||
| Gross Profit | -- | -- | -- | -- | -- | -- | -- | $245.5M | $296.4M | $450.6M | ||
| OPERATING EXPENSES | ||||||||||||
| Operating Expenses | -- | -- | -- | -- | -- | -- | -- | $196.1M | $307.0M | $369.8M | ||
| Research & Development | -- | -- | -- | -- | -- | -- | -- | $34.3M | $44.6M | $51.7M | ||
| Research Expense | -- | -- | -- | -- | -- | -- | -- | $34.3M | $44.6M | -- | ||
| Selling, General & Administrative | -- | -- | -- | -- | -- | -- | -- | $161.7M | $249.6M | $317.7M | ||
| Selling & Marketing Expenses | -- | -- | -- | -- | -- | -- | -- | $161.7M | $249.6M | $317.7M | ||
| Depreciation & Amortization | -- | -- | -- | -- | -- | -- | -- | -- | $5.3M | $382.0K | ||
| Other Operating Expenses | -- | -- | -- | -- | -- | -- | -- | $159.0K | $7.5M | -- | ||
| OPERATING INCOME | ||||||||||||
| Operating income | -- | -- | -- | -- | -- | -- | -- | $49.4M | $-10.6M | $80.8M | ||
| EBITDA | -- | -- | -- | -- | -- | -- | -- | $110.5M | $74.1M | $207.3M | ||
| NON-OPERATING ITEMS | ||||||||||||
| Interest Expense (Non-Operating) | -- | -- | -- | -- | -- | -- | -- | $26.9M | $17.6M | $20.1M | ||
| Net Non-Operating Interest Income/Expense | -- | -- | -- | -- | -- | -- | -- | $-26.9M | $-17.6M | $-20.1M | ||
| Other Income/Expense | -- | -- | -- | -- | -- | -- | -- | $-2.5M | $-3.4M | $-35.0M | ||
| Other Special Charges | -- | -- | -- | -- | -- | -- | -- | $1.1M | $4.0M | $1.9M | ||
| SPECIAL ITEMS | ||||||||||||
| Restructring And Mn A Income | -- | -- | -- | -- | -- | -- | -- | $1.1M | -- | -- | ||
| Special Income Charges | -- | -- | -- | -- | -- | -- | -- | $-1.1M | -- | -- | ||
| Other Impairment Of Capital Assets | -- | -- | -- | -- | -- | -- | -- | $112.0K | $7.6M | $767.0K | ||
| PRE-TAX INCOME | ||||||||||||
| EBIT | -- | -- | -- | -- | -- | -- | -- | $50.8M | $-7.2M | $115.9M | ||
| Pre-Tax Income | -- | -- | -- | -- | -- | -- | -- | $23.8M | $-24.8M | $95.8M | ||
| INCOME TAX | ||||||||||||
| Tax Provision | -- | -- | -- | -- | -- | -- | -- | -- | $3.7M | $17.5M | ||
| NET INCOME | ||||||||||||
| Net Income | -- | -- | -- | -- | -- | -- | -- | $23.8M | $-28.5M | $78.3M | ||
| Net Income (Continuing Operations) | -- | -- | -- | -- | -- | -- | -- | $23.8M | $-28.5M | $78.3M | ||
| Net Income (Discontinued Operations) | -- | -- | -- | -- | -- | -- | -- | $23.8M | $-28.5M | $78.3M | ||
| Net Income (Common Stockholders) | -- | -- | -- | -- | -- | -- | -- | $22.2M | $-30.2M | $77.2M | ||
| Normalized Income | -- | -- | -- | -- | -- | -- | -- | $18.6M | $-17.0M | $95.6M | ||
| TOTALS | ||||||||||||
| Total Expenses | -- | -- | -- | -- | -- | -- | -- | $437.4M | $625.0M | $802.5M | ||
| SHARE & EPS DATA | ||||||||||||
| Average Shares Outstanding | $11.4M | $11.5M | $11.7M | $11.8M | $12.0M | $12.6M | $16.3M | $18.0M | $19.3M | $20.1M | ||
| Average Shares Outstanding (Diluted) | $11.6M | $11.5M | $11.8M | $12.0M | $12.0M | $12.6M | $16.3M | $18.2M | $19.3M | $21.2M | ||
| Shares Outstanding | -- | -- | -- | -- | -- | -- | -- | $22.5M | $22.5M | $23.1M | ||
| Basic EPS | $0.34 | $-0.09 | $1.31 | $0.51 | $-1.88 | $-3.4 | $-3.05 | $0.86 | $-1.04 | $3.5 | ||
| Basic EPS (Continuing Operations) | $0.34 | $-0.09 | $1.31 | $0.51 | $-1.88 | $-3.4 | $-3.05 | $0.86 | $-1.04 | $3.5 | ||
| Diluted EPS | $0.34 | $-0.09 | $1.3 | $0.50 | $-1.88 | $-3.4 | $-3.05 | $0.85 | $-1.04 | $3.32 | ||
| Diluted EPS (Continuing Operations) | $0.34 | $-0.09 | $1.3 | $0.50 | $-1.88 | $-3.4 | $-3.05 | $0.85 | $-1.04 | $3.32 | ||
| Dividend Per Share | -- | -- | -- | -- | -- | $7.6 | -- | -- | -- | -- | ||
| OTHER METRICS | ||||||||||||
| Accrued Preferred Stock Dividends | -- | -- | -- | -- | -- | -- | -- | $1.6M | $1.6M | $1.2M | ||
| Depletion | -- | -- | -- | -- | -- | -- | -- | -- | $5.3M | $382.0K | ||
| Gain On Sale Of P P E | -- | -- | -- | -- | -- | -- | -- | -- | $5.3M | -- | ||
| Other Costof Revenue | -- | -- | -- | -- | -- | -- | -- | $181.5M | $250.2M | $341.3M | ||
| Preferred Stock Dividends | -- | -- | -- | -- | -- | -- | -- | $1.6M | $1.6M | $1.2M | ||
| Restruct | -- | -- | -- | -- | -- | -- | -- | $1.1M | -- | -- | ||
Financial data is updated quarterly and may not reflect the most recent earnings.
| A | B | C | D | |
|---|---|---|---|---|
| 1 | Symbol | Price | Change | Vol |
| 2 | ANIP | $81.41 | -1.6% | 456.07K |
| 3 | ||||
| 4 | ||||
| 5 | ||||
| 6 |
Get ANI Pharmaceuticals Inc. Data in Excel
Stream real-time data directly to your spreadsheets
BUY NOW